Immunotherapy Signal Falls Short on Overall Survival Daniela Ovadia, MD

https://www.medscape.com/viewarticle/immunotherapy-signal-falls-short-overall-survival-2026a10015sd?src= Treatment options remain limited for patients with advanced hormone receptor-positive (HR+) and HER2-negative breast cancer whose disease has progressed after endocrine therapy. Results from the phase 3 KEYNOTE-B49 study (abstract LBA51) suggest a possible role for immunotherapy, but the benefit was limited.